CompanyBHVNNYSENew Haven, CT

Biohaven Ltd.

Biohaven develops opakalim, a Kv7.2/7.3 potassium channel activator for epilepsy treatment.

SEC EDGAR ClinicalTrials.gov biohaven.com

8-KSep 11Latest SEC filing, period to Sep 8

Aug 26Latest story

August 2026

Biohaven files license and assignment agreements for SK Biopharmaceuticals Kv7 deal

Aug 26PartnershipBiohaven Ltd.

Biohaven advances degrader and epilepsy pipelines, reports Q2 2026 results

Aug 10Quarterly updateBHV-1300 Biohaven Ltd.

Biohaven adds John Yetimoglu to board of directors

Aug 7PeopleBiohaven Ltd.

July 2026

Biohaven announces leadership changes as Car retires, Pirman promoted

Jul 9PeopleBiohaven Ltd.